Combination therapies in T2DM exert differential effect on intrarenal haemodynamics
20 Nov 2019
byJairia Dela Cruz
Combination therapy with empagliflozin plus linagliptin (E+L) reduces glomerular filtration rate (GFR), whereas metformin plus insulin glargine (M+I) confers benefits for both GFR and renal plasma flow (RPF) in type 2 diabetes mellitus (T2DM). The haemodynamic mechanism underlying these effects involves a decrease in efferent resistance with E+L and an increase in afferent resistance with M+I, according to the results of a randomized controlled trial presented at the American Society of Nephrology (ASN) Kidney Week 2019.